-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Castle Biosciences, Raises Price Target to $50

Benzinga·12/22/2025 12:48:27
Listen to the news
Canaccord Genuity analyst Kyle Mikson maintains Castle Biosciences (NASDAQ:CSTL) with a Buy and raises the price target from $37 to $50.